GLP-1 Drug Use During Cancer Immunotherapy Linked to Mortality and Immune Side Effects | Research

The takeaway

Using GLP-1 receptor agonists at the start of immune checkpoint inhibitor cancer therapy was associated with changes in mortality and immune-related adverse events in patients with type 2 diabetes.

2,903 matched pairs
Largest study to date examining GLP-1 and immunotherapy drug interactions

What the researchers found

Concurrent GLP-1 receptor agonist use at immune checkpoint inhibitor initiation was associated with mortality and immune-related adverse events in cancer patients with type 2 diabetes.

Why it matters

Millions of patients now take GLP-1 drugs for diabetes or weight loss. As cancer immunotherapy expands, understanding drug interactions between these two major medication classes is critical for patient safety.

How the study worked

Target-trial emulation using TriNetX US Collaborative Network; propensity-score-matched 1:1 design; 2,903 matched pairs; intention-to-treat analysis.

What this study cannot tell us

Observational study design cannot prove causation; potential residual confounding despite propensity matching; database study lacks granular clinical details.

How to read the evidence

Target-trial emulation with propensity matching — rigorous observational design but cannot establish causation.

When this study was published

Published in 2026, addressing a timely question as GLP-1 use expands alongside immunotherapy adoption.

The bigger picture

GLP-1 drugs modulate the immune system beyond just metabolism. This study raises important questions about whether their immunomodulatory effects could interfere with — or potentially enhance — cancer immunotherapy, with profound implications for the growing population using both drug classes.

Questions still open

Should oncologists consider pausing GLP-1 drugs during immune checkpoint inhibitor treatment?
Could GLP-1 drugs' immunomodulatory effects actually enhance immunotherapy responses in some cancer types?

Common questions

Should I stop my GLP-1 drug if I start cancer immunotherapy?

This study found associations between concurrent use and certain outcomes, but cannot prove causation. Discuss with your oncologist and endocrinologist — do not stop medications without medical guidance.

How might GLP-1 drugs affect cancer immunotherapy?

GLP-1 drugs have immunomodulatory effects beyond blood sugar control. They may alter immune cell function in ways that interact with checkpoint inhibitors, potentially affecting both treatment efficacy and side effects.

Read the original research

GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation.

Diabetes research and clinical practice, 231, 113073

View on PubMed ↗Publisher’s paper ↗

Citation

Chan, Shan-Ho; Li, Pei-Yun; Li, Pin-Hung; Lin, Yu-Jung; Wang, Wei-Hsun; Huang, Yu-Nan; Chen, Jia-Yuh. (2026). GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation.. Diabetes research and clinical practice, 231, 113073. https://doi.org/10.1016/j.diabres.2025.113073